Tailin Biotech announced that the cumulative deviation value of the company's stock price increase exceeded 30% for three consecutive trading days on May 7, May 8, and May 9, 2024, which is an abnormal fluctuation in stock trading. After verification, the information disclosed by the company in the early stages did not require correction or addition; the company did not find any recent public media reports of undisclosed material information that may or have had a significant impact on the trading price of the company's stock; there have been no major changes in the company's business situation or internal and external business environment; the company, controlling shareholders and actual controllers have no significant matters relating to the company that should be disclosed but not disclosed, or are in the planning stage; the company did not violate fair information disclosure regulations; the company did not violate fair information disclosure regulations Other situations.
泰林生物：经营情况及内外部经营环境未发生重大变化
Tailin Biotech: There have been no major changes in the business situation and internal and external business environment
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.